Ben Taylor compensation by year
RECURSION PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $53,392 | $538,680 |
| Bonus | $0 | $0 |
| Stock awards | $2,255,389 | $253,881 |
| Option awards | $5,662,543 | $323,110 |
| Non-equity incentive | $200,327 | $205,226 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $7,586 |
| Total | $8,171,651 | $1,328,483 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001601830-26-000065, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 277,759 | $1,136,034 | — |
| RSU | 102,186 | $417,941 | — |
| RSU | 81,479 | $333,249 | — |
| RSU | 45,829 | $187,441 | — |
| RSU | 31,935 | $130,614 | — |
| RSU | 28,454 | $116,377 | — |
| RSU | 3,533 | $14,450 | — |
| Option | 555,517 | — | $6.09 |
| Option | 55,447 | — | $7.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RECURSION PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-15 | Tax withholding | — | 5,396 | $3.41 | 1,071,462 |
| 2026-08-17 | Tax withholding | — | 25,018 | $3.16 | 1,076,858 |
| 2026-06-15 | Tax withholding | — | 5,396 | $3.15 | 1,101,876 |
| 2026-05-15 | Tax withholding | — | 25,018 | $3.04 | 1,107,272 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments RECURSION PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $404,010 | $0 | $20,256 | $424,266 |
| Change in control and involuntary termination | $538,680 | $2,336,106 | $27,008 | $3,440,474 |
Per the Potential Payments Upon Termination or Change in Control table in RECURSION PHARMACEUTICALS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
RECURSION PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Gibson | Former Chief Executive Officer and President and current Chair of the Board | $9,607,508 |
| Najat Khan | Chief Executive Officer and President | $5,349,065 |
| Ben Taylor · this page | Chief Financial Officer and President of Recursion UK | $1,328,483 |
The full RECURSION PHARMACEUTICALS compensation record
free company briefThis page is one person within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RECURSION PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RECURSION PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat